Sign In
Buy SON
$48.50
-0.670 (-1.36%)
At Close: Jun 03, 2026
Zacks Industry Outlook Packaging Corporation of America, Amcor, AptarGroup and Sonoco Products
06:00am, Thursday, 13'th Feb 2025
Packaging Corporation of America, Amcor, AptarGroup and Sonoco Products have been highlighted in this Industry Outlook article.
Sonoco Declares Regular Quarterly Common Stock Dividend
09:00pm, Wednesday, 12'th Feb 2025
HARTSVILLE, S.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Sonoco (NYSE: SON) has declared a $0.52 per share quarterly common stock dividend.
Clark Joins Sonoco Board of Directors
09:00pm, Wednesday, 12'th Feb 2025
HARTSVILLE, S.C., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Sonoco Products Company (“Sonoco” or the “Company”) (NYSE: SON), a global leader in high-value sustainable packaging, today announced that S
Sonoco (SON) Earnings Expected to Grow: Should You Buy?
11:06am, Tuesday, 11'th Feb 2025
Sonoco (SON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sonoco To Report Fourth Quarter and Full Year 2024 Results
09:00am, Monday, 03'rd Feb 2025
HARTSVILLE, S.C., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Sonoco Products Company (“Sonoco” or the “Company”)(NYSE: SON), a global leader in high-value sustainable packaging, will announce fourth qu
SON or PKG: Which Is the Better Value Stock Right Now?
12:46pm, Tuesday, 28'th Jan 2025
Investors interested in Containers - Paper and Packaging stocks are likely familiar with Sonoco (SON) and Packaging Corp. (PKG). But which of these two stocks presents investors with the better value
Should Value Investors Buy Sonoco (SON) Stock?
10:41am, Tuesday, 28'th Jan 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Pick These 5 Bargain Stocks With Impressive EV-to-EBITDA Ratios
07:41am, Tuesday, 28'th Jan 2025
We have screened bargain stocks SM, SON, LOCO, GBX and PAGP based on the EV-to-EBITDA ratio, which gives the true picture of valuation and earnings potential.
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas
09:05am, Tuesday, 21'st Jan 2025
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters combination evaluation with trabectedin (Yondelis ® ) wit
Fairmarkit Expands Latin American Impact Through Partnership with Sonoco
09:00am, Tuesday, 07'th Jan 2025
BOSTON--(BUSINESS WIRE)--Fairmarkit, a leading AI-powered autonomous sourcing solutions provider, today announced its expanded partnership with Sonoco, a global leader in high-value sustainable packag
Sonoco Announces Senior Leadership Changes for 2025
09:00am, Monday, 06'th Jan 2025
HARTSVILLE, S.C., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Sonoco Products Company (“Sonoco” or the “Company”) (NYSE: SON), a global leader in high-value sustainable packaging, today announced senior
Sonoco Inks Agreement to Sell TFP Business to Focus on Core Business
08:36am, Thursday, 19'th Dec 2024
SON inks sell agreement of its TFP Business for $1.8 billion to focus on core businesses and lower debt levels.
TOPPAN Holdings Acquires Sonoco's TFP Business
09:21pm, Wednesday, 18'th Dec 2024
Agreement reached on acquisition of Sonoco's TFP business as TOPPAN Group accelerates expansion of sustainable packaging business in Americas TOKYO , Dec. 18, 2024 /PRNewswire/ -- TOPPAN Holdings Inc
Sonoco Completes Strategic Review, Announces Agreement to Sell Thermoformed and Flexibles Packaging (TFP) Business to TOPPAN Holdings Inc.
05:00pm, Wednesday, 18'th Dec 2024
HARTSVILLE, S.C., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Sonoco Products Company (“Sonoco” or the “Company”) (NYSE: SON), a global leader in high-value sustainable packaging, today announced it has
The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg, without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level
